Experimental basis for the development of a synthetic vaccine against Plasmodium falciparum malaria sporozoites.
Malaria continues to cause extensive morbidity and mortality in man. The exact number of individuals affected is not known. Estimates vary from 200 to 400 million, and more than one million die each year. Protective immunity against malaria can be obtained by vaccination with irradiated sporozoites. The protective antigens are polypeptides (circumsporozoite [CS] proteins) which cover the surface membrane of the parasite. CS proteins contain species-specific immunodominant epitopes, formed by tandem repeated sequences of amino acids. The dominant epitope of Plasmodium falciparum is represented in the synthetic peptide asparagine-alanine-asparagine-proline repeated in tandem three times; that is, (NANP)3. Monoclonal antibodies and most or all polyclonal human antibodies to P. falciparum sporozoites react with (NANP)3. Polyclonal antibodies raised against the synthetic peptide (NANP)3 react with the surface of the parasite and neutralize its infectivity. Since (NANP)3 repeats are present worldwide in CS proteins from P. falciparum, this epitope is a logical target for vaccine development.
D000818:Animals; D000953:Antigens, Protozoan / Q000302:isolation & purification; D000954:Antigens, Surface / Q000276:immunology; D000939:Epitopes / Q000276:immunology; D006801:Humans; D008288:Malaria / Q000517:prevention & control*; D010455:Peptides / Q000138:chemical synthesis / Q000276:immunology; D010963:Plasmodium falciparum / Q000276:immunology*; D015800:Protozoan Proteins; D014612:Vaccines / Q000302:isolation & purification*
D000953:Antigens, Protozoan; D000954:Antigens, Surface; D000939:Epitopes; D010455:Peptides; D015800:Protozoan Proteins; D014612:Vaccines; C041595:circumsporozoite protein, Protozoan